MyFinsight
Home
Blog
About
Cash and cash
equivalents
$257,606K
(-62.68%↓ Y/Y)
Prepaid expenses and
other current assets
$7,027K
(-73.76%↓ Y/Y)
Current income tax
receivable
$2,250K
Total current assets
$266,883K
(-63.58%↓ Y/Y)
Operating lease
right-of-use assets
$15,553K
(-13.94%↓ Y/Y)
Property and equipment,
net
$3,715K
(-23.18%↓ Y/Y)
Restricted cash
$1,449K
(0.00%↑ Y/Y)
Total assets
$287,600K
(-62.02%↓ Y/Y)
Total liabilities and
stockholders' equity
$287,600K
(-62.02%↓ Y/Y)
Total stockholders'
equity
$262,320K
(-62.88%↓ Y/Y)
Total liabilities
$25,280K
(-49.87%↓ Y/Y)
Accumulated deficit
-$534,183K
(-18.44%↓ Y/Y)
Treasury stock, at cost
21,126,760 shares as of...
$384,558K
Additional paid-in capital
$1,181,057K
(2.01%↑ Y/Y)
Operating lease
liabilities, net of current...
$13,127K
(-16.52%↓ Y/Y)
Total current
liabilities
$12,153K
(-64.98%↓ Y/Y)
Common stock, par value
of 0.0001 per share...
$4K
(0.00%↑ Y/Y)
Accrued expenses and
other current...
$7,740K
(-61.23%↓ Y/Y)
Current portion of
operating lease...
$2,597K
(16.46%↑ Y/Y)
Accounts payable
$1,816K
(-65.52%↓ Y/Y)
Back
Back
Balance Sheet
Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. (KROS)
source: myfinsight.com